EUCTR2010-021146-22-GB进行中（未招募）1 期
Alemtuzumab and rheumatoid arthritis - an immunisation study - Alemtuzumab and rheumatoid arthritis - an immunisation study
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 17
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •All study participants must be able and willing to provide informed consent prior to any study-specific procedures, including immunisation. NOTE: Alemtuzumab recipients who do not wish to take part in the study (i.e. attend Addenbrooke’s for study procedures as outlined in Protocol Section 13.1, including blood samples with/without vaccination), but who are happy for morbidity information only to be collected via a phone call or via GP records on one occasion only (as per screening/baseline visit) will indicate their intention in writing on the study Expression of Interest” form. Alemtuzumab recipients (cases) • Received alemtuzumab in original Cambridge studies (1991-94) Matched controls • Rheumatoid arthritis according to 1987 ACR criteria • Disease duration within 5 years of matched case • Age within 10 years of matched case • Gender profile to match alemtuzumab recipients
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 16
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 24
排除标准
- •Both groups • Contra-indications to vaccination (as per SmPCs – see protocol Appendices B-D) • Recent vaccination with study strain of flu vaccine • Vaccination with tetanus, diphtheria, polio or pneumococcus within past 5 years (contra-indication to the specific vaccine only) Controls only • Received rituximab within past 3 months • Treatment with any investigational agent within 12 weeks or 5 half-lives of the investigational drug NOTE: Eligible patients (control or alemtuzumab cohort) who have received vaccination with pneumococcus, tetanus, diphtheria, or polio within the past 5 years will not be excluded from the study, but will NOT be revaccinated with the specific vaccine as relevant, i.e. Revaxis and/or Pneumovax II. NOTE: Eligible patients (control or alemtuzumab cohort) who are also women of child-bearing potential will have pregnancy status checked by a serum pregnancy test at the screening visit. Women who are subsequently confirmed as pregnant or who are breast feeding will NOT be excluded from the study but will NOT receive any of the three vaccines at the screening/baseline visit. Results from the serum pregnancy test (where relevant) must be obtained prior to vaccination. For relevant female patients whose pregnancy test is negative, a separate baseline visit is needed for vaccination only (once pregnancy results are known). The separate baseline visit must be within 7 days of the screening visit; the date of vaccination (baseline) would then be Day 0.
研究者
相似试验
招募中
不适用
Impact of alemtuzumab exposure on immune reconstitution, autoimmunity, risk of infection, chimerism and graft-versus-host disease in children with non-malignant diseases undergoing allogeneic stem celltransplantation - an International Multicenter Observational Study.NL-OMON22218eiden University Medical Center30
招募中
不适用
Cellular immunity after alemtuzumabMultiple sclerosisG35DRKS00011205niversitätsklinikum Köln20
招募中
4 期
Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective PotentialG35.10DRKS00007777niversitätsklinikum Münster, Dr. Christoph Hoppenheit15
进行中（未招募）
1 期
Investigation on how alemtuzumab acts in patients with relapsing remitting multiple sclerosis.EUCTR2014-000709-10-DEniversitätsklinikum Münster15
进行中（未招募）
1 期
Adalimumab in rheumatoid arthritis. An investigation of changes in disease activity and course of joint destruction by use of 3 Tesla Whole-Body MRI, dedicated 3 Tesla MRI and CT of the hand, and soluble biomarkers.Whole-Body MRI in Rheumatoid Arthritis Protocol (WRAP)Reumatoid artritisMedDRA version: 12.1Level: LLTClassification code 10003268Term: Arthritis rheumatoidEUCTR2009-014394-41-DKHvidovre Hospital